The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Open accessAbstract
Troglitazone (CS-045) is one of the thiazolidinediones that activate the peroxisome proliferator-activated receptor gamma (PPARgamma), which is expressed primarily in adipose tissues. To elucidate the mechanism by which troglitazone relieves insulin resistance in vivo, we studied its effects on the white adipose tissues of an obese animal model (obese Zucker rat). Administration of troglitazone for 15 d normalized mild hyperglycemia and marked hyperinsulinemia in these rats. Plasma triglyceride level was decreased by troglitazone in both obese and lean rats. Troglitazone did not change the total weight of white adipose tissues but increased the number of small adipocytes (< 2,500 micron2) approximately fourfold in both retroperitoneal and subcutaneous adipose tissues of obese rats. It also decreased the number of large adipocytes (> 5,000 micron2) by approximately 50%. In fact, the percentage of apoptotic nuclei was approximately 2.5-fold higher in the troglitazone-treated retroperitoneal white adipose tissue than control. Concomitantly, troglitazone normalized the expression levels of TNF-alpha which were elevated by 2- and 1.4-fold in the retroperitoneal and mesenteric white adipose tissues of the obese rats, respectively. Troglitazone also caused a dramatic decrease in the expression levels of leptin, which were increased by 4-10-fold in the white adipose tissues of obese rats. These results suggest that the primary action of troglitazone may be to increase the number of small adipocytes in white adipose tissues, presumably via PPARgamma. The increased number of small adipocytes and the decreased number of large adipocytes in white adipose tissues of troglitazone-treated obese rats appear to be an important mechanism by which increased expression levels of TNF-alpha and higher levels of plasma lipids are normalized, leading to alleviation of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093 · cited 1×
“Circulating lipids such as FFA, which are increased in obesity, inhibit glucose uptake and use in muscle through Randle’s cycle (9, 10).”
BackgroundLehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Elective induction versus spontaneous labor after sonographic diagnosis of fetal macrosomia.
Combs, C. A., Singh, N. B., & Khoury, J. C. (1993) · PubMed · Cited by 2,499
Cited by
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824
Self-citation(1998) · PubMed · Cited by 2,737
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Adipogenesis and metabolic health
Ghaben, A. L., & Scherer, P. E. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0093-z · Cited by 1,395
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Self-citationPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“A stimulatory effect of thiazolidinediones to increase the number of adipocytes is well established (125, 134, 135) and explains, in large part, the weight gain and reduction in circulating free fatty acid levels (128) observed with all thiazolidinedione therapy.”
BackgroundHotta, K., Funahashi, T., Bodkin, N. L., Ortmeyer, H. K., Arita, Y., Hansen, B. C., & Matsuzawa, Y. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1126 · Cited by 1,072
Adiponectin: More Than Just Another Fat Cell Hormone?
Chandran, M., Phillips, S. A., Ciaraldi, T., & Henry, R. R. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2442 · Cited by 1,008
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536828100 · Cited by 976
Chinetti, G., Fruchart, J.-C., & Staels, B. (2000) · Inflammation Research · doi:10.1007/s000110050622 · Cited by 954
Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N., Ohtsuka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601284200 · Cited by 917
Self-citationWeyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Adipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Molecular Regulation of Adipogenesis and Potential Anti-Adipogenic Bioactive Molecules
Moseti, D., Regassa, A., & Kim, W.-K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010124 · Cited by 736
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Moller, D. E. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00272-1 · Cited by 718
Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice
Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., et al. (2009) · Diabetes · doi:10.2337/db08-1475 · Cited by 715
Self-citationPPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
Gavrilova, O., Marcus-Samuels, B., Graham, D., Kim, J. K., Shulman, G. I., Castle, A. L., Vinson, C., Eckhaus, M., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7901 · Cited by 676
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103241200 · Cited by 637
Self-citationNuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., Straubhaar, J., Czech, M. P., & Corvera, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21752 · Cited by 616
“It is relevant that the staining pattern found in adipocytes from rosiglitazone-treated animals was seen in cells of a size equal to those from 26-week-old untreated animals, a finding that suggests that not only small cells (8) but also large cells within the adipose tissue are susceptible to the actions of rosiglita…”
BackgroundThe role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance
Goossens, G. H. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.10.010 · Cited by 591
Peroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Peroxisome-proliferator-activated receptors and cancers: complex stories
Michalik, L., Desvergne, B., & Wahli, W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1254 · Cited by 573
Combs, T. P., Wagner, J. A., Berger, J., Doebber, T., Wang, W.-J., Zhang, B. B., Tanen, M., Berg, A. H., O’Rahilly, S., Savage, D. B., et al. (2002) · Endocrinology · doi:10.1210/endo.143.3.8662 · Cited by 565
Regulation of adipocytokines and insulin resistance
Fasshauer, M., & Paschke, R. (2003) · Diabetologia · doi:10.1007/s00125-003-1228-z · Cited by 545
Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation
Ristow, M., Müller-Wieland, D., Pfeiffer, A., Krone, W., & Kahn, C. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391403 · Cited by 545
Failure of adipocyte differentiation causes type II diabetes mellitus?
Danforth, E. (2000) · Nature Genetics · doi:10.1038/79111 · Cited by 487
Sharma, A. M., & Staels, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1268 · Cited by 479
Furuhashi, M., Ura, N., Higashiura, K., Murakami, H., Tanaka, M., Moniwa, N., Yoshida, D., & Shimamoto, K. (2003) · Hypertension · doi:10.1161/01.hyp.0000078490.59735.6e · Cited by 461
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440
Inflamed Adipose Tissue: A Culprit Underlying the Metabolic Syndrome and Atherosclerosis
Gustafson, B., Hammarstedt, A., Andersson, C. X., & Smith, U. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147835 · Cited by 436
Risérus, U., Arner, P., Brismar, K., & Vessby, B. (2002) · Diabetes Care · doi:10.2337/diacare.25.9.1516 · Cited by 435
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Adipocyte Differentiation: From Fibroblast to Endocrine Cell
Gregoire, F. M. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122601106 · Cited by 433
Norris, A. W., Chen, L., Fisher, S. J., Szanto, I., Ristow, M., Jozsi, A. C., Hirshman, M. F., Rosen, E. D., Goodyear, L. J., Gonzalez, F. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17305 · Cited by 417
Peirce, V., Carobbio, S., & Vidal-Puig, A. (2014) · Nature · doi:10.1038/nature13477 · Cited by 415
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Yang, W.-S., Jeng, C.-Y., Wu, T.-J., Tanaka, S., Funahashi, T., Matsuzawa, Y., Wang, J.-P., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.376 · Cited by 405
PPARγ in adipocyte differentiation and metabolism – Novel insights from genome‐wide studies
Siersbæk, R., Nielsen, R., & Mandrup, S. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.010 · Cited by 400
Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1
Ma, L.-J., Mao, S.-L., Taylor, K. L., Kanjanabuch, T., Guan, Y., Zhang, Y., Brown, N. J., Swift, L. L., McGuinness, O. P., Wasserman, D. H., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.2.336 · Cited by 397
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Impaired Preadipocyte Differentiation in Human Abdominal Obesity
Isakson, P., Hammarstedt, A., Gustafson, B., & Smith, U. (2009) · Diabetes · doi:10.2337/db08-1770 · Cited by 369
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
de Souza, C. J., Eckhardt, M., Gagen, K., Dong, M., Chen, W., Laurent, D., & Burkey, B. F. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1863 · Cited by 350
The Protein Kinase IKKɛ Regulates Energy Balance in Obese Mice
Chiang, S.-H., Bazuine, M., Lumeng, C. N., Geletka, L. M., Mowers, J., White, N. M., Ma, J.-T., Zhou, J., Qi, N., Westcott, D., et al. (2009) · Cell · doi:10.1016/j.cell.2009.06.046 · Cited by 344
The developmental origins of adipose tissue
Berry, D. C., Stenesen, D., Zeve, D., & Graff, J. M. (2013) · Development · doi:10.1242/dev.080549 · Cited by 343
The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism
Stumvoll, M., & Häring, H. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2341 · Cited by 332
Kubota, N., Terauchi, Y., Kubota, T., Kumagai, H., Itoh, S., Satoh, H., Yano, W., Ogata, H., Tokuyama, K., Takamoto, I., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m505649200 · Cited by 326
Self-citationPPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Janke, J., Engeli, S., Gorzelniak, K., Luft, F. C., & Sharma, A. M. (2002) · Diabetes · doi:10.2337/diabetes.51.6.1699 · Cited by 322
Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0217 · Cited by 321
Kang, J., Tsuyoshi, G., Han, I., Kawada, T., Kim, Y. M., & Yu, R. (2010) · Obesity · doi:10.1038/oby.2009.301 · Cited by 313
Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12864 · Cited by 308
Self-citationEfficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Lipotoxicity, overnutrition and energy metabolism in aging
Slawik, M., & Vidal-Puig, A. J. (2006) · Ageing Research Reviews · doi:10.1016/j.arr.2006.03.004 · Cited by 300
Hibuse, T., Maeda, N., Funahashi, T., Yamamoto, K., Nagasawa, A., Mizunoya, W., Kishida, K., Inoue, K., Kuriyama, H., Nakamura, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503291102 · Cited by 297
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Satoh, N., Ogawa, Y., Usui, T., Tagami, T., Kono, S., Uesugi, H., Sugiyama, H., Sugawara, A., Yamada, K., Shimatsu, A., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2493 · Cited by 289
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Effect of thiazolidinediones on body weight in patients with diabetes mellitus
Fonseca, V. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.005 · Cited by 283
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Flachs, P., Rossmeisl, M., Bryhn, M., & Kopecky, J. (2009) · Clinical Science · doi:10.1042/cs20070456 · Cited by 286
Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells
Sharma, A. M., Janke, J., Gorzelniak, K., Engeli, S., & Luft, F. C. (2002) · Hypertension · doi:10.1161/01.hyp.0000036448.44066.53 · Cited by 283
Variation in Type 2 Diabetes-Related Traits in Mouse Strains Susceptible to Diet-Induced Obesity
Rossmeisl, M., Rim, J. S., Koza, R. A., & Kozak, L. P. (2003) · Diabetes · doi:10.2337/diabetes.52.8.1958 · Cited by 283
Larsen, T. M., Toubro, S., & Astrup, A. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.802223 · Cited by 282
Regulation of adipocyte differentiation and function by polyunsaturated fatty acids
Madsen, L., Petersen, R. K., & Kristiansen, K. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.03.001 · Cited by 281
Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’
Lundgren, M., Svensson, M., Lindmark, S., Renström, F., Ruge, T., & Eriksson, J. W. (2007) · Diabetologia · doi:10.1007/s00125-006-0572-1 · Cited by 277
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
Dewulf, E. M., Cani, P. D., Neyrinck, A. M., Possemiers, S., Holle, A. V., Muccioli, G. G., Deldicque, L., Bindels, L. B., Pachikian, B. D., Sohet, F. M., et al. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.05.009 · Cited by 269
Mesenteric fat in Crohn’s disease: a pathogenetic hallmark or an innocent bystander?
Peyrin-Biroulet, L., Chamaillard, M., Gonzalez, F., Beclin, E., Decourcelle, C., Antunes, L., Gay, J., Neut, C., Colombel, J.-F., & Desreumaux, P. (2007) · Gut · doi:10.1136/gut.2005.082925 · Cited by 264
Malloy, V. L., Krajcik, R. A., Bailey, S. J., Hristopoulos, G., Plummer, J. D., & Orentreich, N. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00220.x · Cited by 263
Role of Adipose Tissue as an Inflammatory Organ in Human Diseases
Schäffler, A., Müller-Ladner, U., Schölmerich, J., & Büchler, C. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0022 · Cited by 258
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228
Stubbins, R. E., Najjar, K., Holcomb, V. B., Hong, J., & Núñez, N. P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01488.x · Cited by 204
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial
Smith, S. R., de Jonge, L., Volaufova, J., Li, Y., Xie, H., & Bray, G. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.07.008 · Cited by 176
“In rodents, this differentiation of fat cells is manifested as an increase in the number of small adipocytes [4,5].”
BackgroundKuda, O., Jelenik, T., Jilkova, Z., Flachs, P., Rossmeisl, M., Hensler, M., Kazdova, L., Ogston, N., Baranowski, M., Gorski, J., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1305-z · Cited by 142
Boden, G., Homko, C., Mozzoli, M., Showe, L. C., Nichols, C., & Cheung, P. (2005) · Diabetes · doi:10.2337/diabetes.54.3.880 · Cited by 129
Modulation of glucose metabolism by the renin-angiotensin-aldosterone system
Favre, G. A., Esnault, V. L. M., & Van Obberghen, E. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2014 · Cited by 114
Tsurutani, Y., Fujimoto, M., Takemoto, M., Irisuna, H., Koshizaka, M., Onishi, S., Ishikawa, T., Mezawa, M., He, P., Honjo, S., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.02.106 · Cited by 102
Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice
Kawasaki, F., Matsuda, M., Kanda, Y., Inoue, H., & Kaku, K. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00128.2004 · Cited by 99
Troglitazone Antagonizes Metabolic Effects of Glucocorticoids in Humans
Willi, S. M., Kennedy, A., Wallace, P., Ganaway, E., Rogers, N. L., & Garvey, W. T. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2895 · Cited by 77
Impact of the renin-angiotensin system on lipid and carbohydrate metabolism
Strazzullo, P., & Galletti, F. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200405000-00010 · Cited by 70
Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation
Bugge, A., & Mandrup, S. (2010) · PPAR Research · doi:10.1155/2010/169506 · Cited by 69
Metadata
- Authors
- Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y., & Kadowaki, T.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-03-15
- Volume
- 101
- Issue
- 6
- Pages
- 1354-1361
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2125090169
- Cited by
- 995
- References
- 51
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.